PHARMA
Adimmune To Begin Phase III Flu Vaccine Trials In China
Taiwanese vaccine maker Adimmune Corp has received approval from the Chinese government to start Phase III clinical trials of its flu vaccine in China.
Ablynx Grants Eddingpharm License To Develop Anti-RANKL Nanobody
Ablynx has granted a license to Eddingpharm to develop and commercialize its anti-RANKL Nanobody, ALX-0141, in China, Hong Kong, Macau and Taiwan.
Charles River Laboratories Acquires BRASS
Charles River Laboratories has acquired BRASS Pte Ltd, a company that manufactures biopharmaceutical and medical products.
University Of Melbourne Develops Therapy For Parkinson’s Disease
The University of Melbourne and Procypra Therapeutics have agreed to develop therapy to treat Parkinson’s disease.
Phase 1/2 Results For Takeda’s Norovirus Vaccine
Takeda has announced the results of a Phase 1/2 study of its norovirus vaccine candidate which was found to be well tolerated.
Hutchison MediPharma And Eli Lilly Collaborate On Cancer Therapy
Hutchison MediPharma has entered into a collaboration with Eli Lilly to develop fruquintinib, a targeted oncology therapy against solid tumors.
ASLAN Pharmaceuticals Secures US$22m In Series B Financing
ASLAN Pharmaceuticals has raised US$22 million after hosting a second round of financing with Cenova Ventures.
Otsuka Pharma Completes Acquisition Of Astex Pharma For US$886m
Otsuka Pharma has successfully completed its acquisition of Astex Pharmaceuticals, Inc. for US$8.50 per share.
PAREXEL Launches Platform For Clinical Trial Registration
PAREXEL has launched a service called China Trials Solution to provide clients with local market knowledge and resources.
